A new trading day began on Tuesday, with Perspective Therapeutics Inc (AMEX: CATX) stock price down -2.50% from the previous day of trading, before settling in for the closing price of $4.0. CATX’s price has ranged from $1.60 to $16.55 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -9.86%. Meanwhile, its annual earnings per share averaged 6.46%. With a float of $54.14 million, this company’s outstanding shares have now reached $74.05 million.
Let’s determine the extent of company efficiency that accounts for 140 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Perspective Therapeutics Inc (CATX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Perspective Therapeutics Inc is 27.07%, while institutional ownership is 65.46%. The most recent insider transaction that took place on Mar 28 ’25, was worth 49,384. In this transaction Chief Executive Officer of this company bought 22,026 shares at a rate of $2.24, taking the stock ownership to the 59,383 shares. Before that another transaction happened on Mar 28 ’25, when Company’s Chief Executive Officer bought 4,650 for $2.21, making the entire transaction worth $10,288. This insider now owns 4,650 shares in total.
Perspective Therapeutics Inc (CATX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.46% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.94% during the next five years compared to -9.86% drop over the previous five years of trading.
Perspective Therapeutics Inc (AMEX: CATX) Trading Performance Indicators
Here are Perspective Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 17.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 196.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.29 in one year’s time.
Technical Analysis of Perspective Therapeutics Inc (CATX)
Looking closely at Perspective Therapeutics Inc (AMEX: CATX), its last 5-days average volume was 1.42 million, which is a jump from its year-to-date volume of 0.99 million. As of the previous 9 days, the stock’s Stochastic %D was 74.24%.
During the past 100 days, Perspective Therapeutics Inc’s (CATX) raw stochastic average was set at 80.99%, which indicates a significant increase from 66.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.33 in the past 14 days, which was higher than the 0.26 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.10, while its 200-day Moving Average is $4.77. However, in the short run, Perspective Therapeutics Inc’s stock first resistance to watch stands at $4.14. Second resistance stands at $4.38. The third major resistance level sits at $4.58. If the price goes on to break the first support level at $3.70, it is likely to go to the next support level at $3.51. Now, if the price goes above the second support level, the third support stands at $3.27.
Perspective Therapeutics Inc (AMEX: CATX) Key Stats
With a market capitalization of 289.49 million, the company has a total of 74,228K Shares Outstanding. Currently, annual sales are 1,450 K while annual income is -79,280 K. The company’s previous quarter sales were 340 K while its latest quarter income was -18,180 K.
